Genomic analysis across 53 canine cancer types reveals novel mutations and high clinical actionability potential

• Published in: Veterinary & comparative oncology Vol. 22; no. 1; pp. 30 - 41
• Main Authors: Sakthikumar, Sharadha, Warrier, Manisha, Whitley, Derick, Facista, Salvatore, Adkins, Jonathan, Aman, Sara, Tsinajinnie, Darwin, Duran, Natalie, Siravegna, Giulia, Ahmed, Zeeshan, Day, Kenneth, Jenkins, Brooklyn, Patel, Nidhi, Ryden, Kirk, Nadai, Joe, Banovich, Kathryn, Powers, Barbara, Edwards, Jeffrey, Steinberg, Jennifer, Fielder, Susan, Wong, Shukmei, Byron, Sara A., Izatt, Tyler, Zismann, Victoria, Boateng, Martin, Zhu, Zhanyang, Chuang, Han‐Yu, Trent, Jeffrey M., Haworth, David, Chon, Esther, Hendricks, William, Wang, Guannan
• Format: Journal Article
• Language: English
• Published: Oxford, UK Blackwell Publishing Ltd 01.03.2024
• Subjects: Animals; Biomarkers, Tumor - genetics; cancer; comparative oncology and genomics; Dog Diseases - genetics; Dogs; genomic diagnostics; Genomics; Humans; Mutation; mutation‐based biomarkers; Neoplasms - genetics; Neoplasms - veterinary; dogs; cancer; comparative oncology and genomics; mutation-based biomarkers; genomic diagnostics
• ISSN: 1476-5810; 1476-5829
• DOI: 10.1111/vco.12944

A genomic understanding of the oncogenic processes and individual variability of human cancer has steadily fueled improvement in patient outcomes over the past 20 years. Mutations within tumour tissues are routinely assessed through clinical genomic diagnostic assays by academic and commercial laboratories to facilitate diagnosis, prognosis and effective treatment stratification. The application of genomics has unveiled a wealth of mutation‐based biomarkers in canine cancers, suggesting that the transformative principles that have revolutionized human cancer medicine can be brought to bear in veterinary oncology. To advance clinical genomics and genomics‐guided medicine in canine oncology, we have developed and validated a canine cancer next‐generation sequencing gene panel for the identification of multiple mutation types in clinical specimens. With this panel, we examined the genomic landscapes of 828 tumours from 813 dogs, spanning 53 cancer types. We identified 7856 alterations, encompassing copy number variants, single nucleotide variants, indels and internal tandem duplications. Additionally, we evaluated the clinical utility of these alterations by incorporating a biomarker framework from comprehensive curation of primary canine literature and inferences from human cancer genomic biomarker literature and clinical diagnostics. Remarkably, nearly 90% of the cases exhibited mutations with diagnostic, prognostic or therapeutic implications. Our work represents a thorough assessment of genomic landscapes in a large cohort of canine cancers, the first of its kind for its comprehensive inclusion of multiple mutation types and structured annotation of biomarkers, demonstrating the clinical potential of leveraging mutation‐based biomarkers in veterinary oncology.